Global Plasma Fractionation Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The Plasma Fractionation Market size is expected to reach USD 96.52 Billion in 2034 from USD 44.18 Billion (2025) growing at a CAGR of 9.07% during 2026-2034.

The Global Plasma Fractionation Market has witnessed steady growth driven by increasing demand for plasma-derived therapies used in treating immune deficiencies, bleeding disorders, and neurological conditions. Plasma fractionation involves separating plasma into its key protein components such as immunoglobulins, albumin, and clotting factors. Rising prevalence of chronic and rare diseases has significantly boosted market demand.

Major growth drivers include advancements in biotechnology, improved plasma collection infrastructure, and growing awareness of plasma-based treatments. Government support for plasma donation programs and expansion of healthcare systems in developing countries further enhance market prospects. Continuous R&D efforts are improving purification techniques and production efficiency.

Looking forward, the market is expected to grow as therapeutic applications expand and global healthcare spending increases. Emerging economies will play a crucial role due to expanding patient access. Innovations in fractionation technology and regulatory harmonization will further strengthen the industry's long-term outlook.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

Albumin
ImmunoglobulinsA ((Intravenous immunoglobulins, Subcutaneous immunoglobulins, Other immunoglobulins))
Coagulation FactorsA (Factor VIII, Factor IX, VON Willebrand Factor, Prothrombin Complex Concentrates, Fibrinogen Concentrates, Others)
Protease inhibitors
Others

By Method

Centrifugation
Depth Filtration
Chromatography
Others

By Application

Neurology
Hematology
Oncology
Immunology
Pulmonology
Others

By End-use

Hospitals & Clinics
Clinical Research
Others

COMPANIES PROFILED

Grifols SA, CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion SpA, LFB SA, Biotest AG, Sanquin, Bio Products Laboratory Ltd, Intas Pharmaceuticals Ltd

We can customise the report as per your requriements

Product Code: VMR11210047

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL PLASMA FRACTIONATION MARKET: BY PRODUCT 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Product
4.2. Albumin Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. ImmunoglobulinsA ((Intravenous immunoglobulins, Subcutaneous immunoglobulins, Other immunoglobulins)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Coagulation FactorsA (Factor VIII, Factor IX, VON Willebrand Factor, Prothrombin Complex Concentrates, Fibrinogen Concentrates, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Protease inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PLASMA FRACTIONATION MARKET: BY METHOD 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Method
5.2. Centrifugation Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Depth Filtration Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Chromatography Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PLASMA FRACTIONATION MARKET: BY APPLICATION 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Application
6.2. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.5. Immunology Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.6. Pulmonology Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PLASMA FRACTIONATION MARKET: BY END-USE 2022-2034 (USD MN)

7.1. Market Analysis, Insights and Forecast End-use
7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Clinical Research Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PLASMA FRACTIONATION MARKET: BY REGION 2022-2034(USD MN)

8.1. Regional Outlook
8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Product
- 8.2.2 By Method
- 8.2.3 By Application
- 8.2.4 By End-use
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Product
- 8.3.2 By Method
- 8.3.3 By Application
- 8.3.4 By End-use
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Product
- 8.4.2 By Method
- 8.4.3 By Application
- 8.4.4 By End-use
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Product
- 8.5.2 By Method
- 8.5.3 By Application
- 8.5.4 By End-use
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 South East Asia
- 8.5.10 Rest of Latin America
8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Product
- 8.6.2 By Method
- 8.6.3 By Application
- 8.6.4 By End-use
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

9.1. Recent Developments
9.2. Company Categorization
9.3. Supply Chain & Channel Partners (based on availability)
9.4. Market Share & Positioning Analysis (based on availability)
9.5. Vendor Landscape (based on availability)
9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PLASMA FRACTIONATION INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Company Profiles
- 10.2.1 Grifols S.A
- 10.2.2 CSL Limited
- 10.2.3 Takeda Pharmaceutical Company Limited
- 10.2.4 Octapharma AG
- 10.2.5 Kedrion S.P.A
- 10.2.6 LFB S.A
- 10.2.7 Biotest AG
- 10.2.8 Sanquin
- 10.2.9 Bio Products Laboratory Ltd
- 10.2.10 Intas Pharmaceuticals Ltd